St. Louis, Missouri Roundup Lawsuit: The Supreme Court Ruled — But Your Case May Not Be Over
You just heard the news. The Supreme Court ruled against Roundup plaintiffs. Bayer’s stock jumped nearly twenty percent. The headlines say Bayer won. And if you or someone you love used Roundup for years and then heard the words “non-Hodgkin’s lymphoma” from an oncologist, you are sitting at a kitchen table right now wondering whether the law just walked away from you.
It did not. Not fully. Not even close to fully. And we are going to tell you exactly why — because the difference between what the ruling did and what Bayer wants you to think it did is the difference between walking away from a valid case and fighting one that can still be won.
We are Attorney911 — The Manginello Law Firm, PLLC. We handle toxic tort and product liability cases in Missouri and nationwide. What follows is not a press release. It is the analysis we would give you if you were sitting across from us, at no cost, hearing the truth about what the Supreme Court actually held and what it left untouched. Call us at 1-888-ATTY-911 and we will give you that conversation for real, any hour, in English or in Spanish.
What the Supreme Court Actually Ruled — and What It Did Not Touch
Here is the single most important sentence in this entire analysis: the Supreme Court’s ruling is narrowly limited to failure-to-warn claims. It does not eliminate all Roundup lawsuits. It does not foreclose every legal theory. It does one specific thing — it holds that the Federal Insecticide, Fungicide, and Rodenticate Act (FIFRA), the federal law governing pesticide labels, preempts state-law claims that would require a cancer warning on Roundup’s label beyond what the EPA approved.
The 7-2 decision reversed a Missouri appellate court decision that had upheld a $1.25 million jury verdict for a St. Louis-area gardener who used Roundup for two decades and developed non-Hodgkin’s lymphoma. That gardener’s claim was built on failure-to-warn — the theory that Monsanto and Bayer should have put a cancer warning on the product label. The Supreme Court said: no, federal law controls what goes on a pesticide label, and state tort law cannot demand a warning the EPA did not require.
The Supreme Court’s decision focused almost entirely on the failure-to-warn cause of action and does not appear to hold that all Roundup lawsuits are preempted.
That quote — from public reporting on the ruling — is the sentence that matters most to you. The Court drew a line. It said failure-to-warn claims based on state law are preempted by federal pesticide labeling law. It did not say design defect claims are preempted. It did not say negligent design claims are preempted. It did not say fraudulent marketing claims are preempted. And Bayer knows this — which is why Bayer’s own statement carefully says the ruling should dismiss “the vast majority of claims,” not “all claims.”
The “vast majority” language is doing a lot of work in that sentence. Bayer is counting on you hearing “vast majority” as “all.” It is not all. And the claims that survive may be the claims worth the most.
The Claims That Are Now Preempted — and the Claims That Survive
Failure to Warn: Now Largely Foreclosed
The primary theory across Roundup litigation has been failure to warn — the argument that Monsanto and Bayer knew or should have known about cancer risks and failed to put a warning on the product label. That theory is now largely preempted. If your case rests entirely on “they should have warned me on the label,” the Supreme Court has made that path extremely difficult, possibly impossible, depending on how lower courts apply the ruling.
This is the theory that drove the $1.25 million verdict in the Durnell case, the early multi-million-dollar verdicts that put Roundup on the national map, and the bulk of the approximately 67,000 pending claims. Bayer is correct that most existing complaints lead with failure-to-warn. That is what “vast majority” means.
Design Defect: Appears to Survive
A design defect claim does not depend on what the label says. It argues that the product itself — its formulation, its active ingredient, its design — is unreasonably dangerous regardless of how it was labeled. The claim does not require a label change. It requires proof that the product was designed in a way that made it dangerous, and that a safer, economically feasible alternative design existed.
This theory appears to survive the Supreme Court’s ruling because it does not collide with FIFRA’s federal labeling scheme. The EPA controls what goes on a pesticide label. It does not control whether the product’s formulation is subject to strict liability under state product liability law when the claim is about the design itself, not the label.
To prove a design defect claim in a Roundup case, you need to show that glyphosate — or the specific Roundup formulation — is unreasonably dangerous by design, and that a safer alternative was technically feasible and commercially practical. That requires expert testimony on formulation chemistry, alternative herbicide designs, and the state of scientific knowledge at the time of manufacture. It also requires internal Monsanto documents showing what the company knew about glyphosate’s carcinogenic potential and whether alternative formulations were studied and rejected.
Negligent Design: Appears to Survive
Negligent design is the companion theory. It argues that the manufacturer was negligent — not just strictly liable — in how it designed, formulated, or tested the herbicide. This is a breach of a duty of reasonable care independent of labeling obligations. The claim survives to the extent it does not reduce to a failure-to-warn argument dressed in different clothing.
The distinction matters. If your negligent design claim is really just “they were negligent because they didn’t warn,” a court may find it preempted alongside failure-to-warn. But if the claim is “they were negligent in choosing this formulation when a safer one was available and they knew it” — that is a design claim, not a warning claim, and it stands on different legal ground.
Fraudulent Marketing and Misrepresentation: Still Viable
Claims targeting promotional materials, public statements, advertising, and marketing practices — not the EPA-approved label — remain viable after the ruling. FIFRA governs pesticide labels. It does not immunize a company from liability for what it says in advertisements, safety brochures, promotional videos, public statements, or dealer communications.
If Monsanto told the public that Roundup was “safe as table salt” — and internal documents show it knew that was not true — that is a marketing claim, not a labeling claim. The Supreme Court’s FIFRA preemption ruling does not reach it.
Breach of Express Warranty: May Survive
Claims based on specific safety representations or warranties made outside the EPA-approved label may survive preemption. If the company made express promises about Roundup’s safety in advertising or dealer materials that turned out to be false, the breach of that promise is a claim independent of what the label did or did not say.
The $7.25 Billion Class Action Settlement: Status and What It Means for You
Hours after the Supreme Court released its decision, Bayer announced that the proposed $7.25 billion Roundup class action settlement will move forward. The settlement has received preliminary approval from Judge Timothy Boyer of the St. Louis Circuit Court and is designed to cover most of the approximately 67,000 claims from plaintiffs who allege glyphosate caused their cancer.
Here is what you need to understand about that number. The $7.25 billion divided across 67,000 claims averages roughly $108,000 per claimant. But that average is misleading — individual allocations will vary based on injury severity, exposure duration, treatment history, and age at diagnosis. Settlement-track cases will likely range from $25,000 on the low end to $500,000 or more for cases with severe disease and strong documented exposure. The settlement is a class action, which means you may be automatically included unless you affirmatively opt out.
This creates the single most important strategic decision facing every Roundup plaintiff right now: do you participate in the class settlement, or do you opt out and pursue an individual design defect claim?
There is no one-size-fits-all answer. But here is how we think about it.
When Settlement Participation May Be the Right Choice
If your causation evidence is weaker — shorter exposure duration, less frequent use, other risk factors for non-Hodgkin’s lymphoma, or a less severe disease presentation — the settlement may provide meaningful compensation without the risk, delay, and cost of individual litigation. The settlement process is faster, more predictable, and does not require you to prove your case to a jury. For many claimants, especially those with moderate injuries and moderate exposure histories, the settlement is a rational path.
When Opting Out and Pursuing Design Defect May Be the Right Choice
If you have documented long-term Roundup exposure — years of regular use as a gardener, landscaper, farmer, or groundskeeper — and a confirmed non-Hodgkin’s lymphoma diagnosis with significant treatment history, your case may be worth substantially more than the settlement allocation. Pre-ruling Roundup verdicts reached multi-million-dollar ranges. Design defect claims that survive preemption carry higher potential verdict values but also higher risk: defense verdicts, protracted litigation, aggressive Daubert challenges to general causation, and the burden of proving a safer alternative design was feasible.
The decision to opt out is irreversible in most class structures. It must be made with full information about your individual case strength under the surviving legal theories. This is not a decision to make based on a news headline. It is a decision to make with a lawyer who has evaluated your specific exposure history, your medical records, and the current state of the science connecting glyphosate to non-Hodgkin’s lymphoma.
Bayer has already paid approximately $10 billion in Roundup settlements and verdicts. The $7.25 billion class settlement is the next chapter, not the final one. Bayer’s CEO has said the settlement will “significantly contain this litigation.” Containment is not elimination. And the Supreme Court ruling, while a significant win for Bayer on failure-to-warn, has not closed the courthouse door on every theory.
Missouri Product Liability Law: What Governs Your Case in St. Louis
The Statute of Limitations
Missouri’s statute of limitations for personal injury actions gives you five years from the date the cause of action accrues. For toxic exposure cases involving latent diseases like cancer, the clock typically does not start on the date of exposure — it starts when you discovered, or reasonably should have discovered, that your injury was connected to the product. This is the discovery rule, and it is critical in Roundup cases because the latency between glyphosate exposure and a non-Hodgkin’s lymphoma diagnosis can span years or decades.
If your loved one died from non-Hodgkin’s lymphoma and you are considering a wrongful death claim, Missouri’s wrongful death statute of limitations is shorter — three years from the date of death. That is a harder deadline, and it runs regardless of when the connection to Roundup was discovered. If you are approaching that window, the time to act is now, not after the settlement approval process concludes.
We are a trial firm that takes Missouri cases. We work with local counsel and appear pro hac vice where required. We do not claim an office in Missouri, and we will not pretend to. What we bring is the experience and resources to handle complex product liability and wrongful death claims — and the honesty to tell you whether your case is better suited to the settlement track or individual litigation.
Missouri’s Comparative Fault Rule
Missouri follows pure comparative fault. This means that if you are partly at fault — say, you used Roundup without wearing protective equipment, or you used it more frequently than the label recommended — your recovery is reduced by your percentage of fault, but it is not eliminated. Even if a jury found you ninety percent at fault, you would still recover ten percent of your damages.
This is more plaintiff-friendly than the modified comparative fault rules in many states, which bar recovery entirely if you are fifty or fifty-one percent at fault. Missouri does not draw that line. Every percentage point the defense tries to pin on you is money, and every percentage point we take off the board goes directly to your recovery.
Damage Caps — or the Lack of Them
Missouri does not impose statutory caps on compensatory damages in product liability actions. The damage caps that exist in Missouri are limited to medical malpractice contexts. This means that in a Roundup product liability case, the full measure of your economic and non-economic damages — medical expenses, lost wages, pain and suffering, emotional distress — is not artificially limited by a statute.
Punitive Damages
Missouri permits punitive damages upon a showing of reckless disregard or conscious disregard for the safety of others. In a Roundup design defect case, punitive damages would require evidence that Monsanto knew its product was dangerous and consciously chose to continue selling it anyway. The internal corporate documents that have already surfaced in prior Roundup litigation — showing debates within Monsanto about glyphosate’s cancer potential, ghostwritten scientific papers, and regulatory influence campaigns — are the raw material for a punitive damages argument. The Supreme Court’s preemption of failure-to-warn claims narrows the evidentiary pathway to punitives in some cases, but design defect and marketing claims that survive preemption can still support a punitive damages theory if the facts support it.
The Defendant: Bayer AG and the Monsanto Corporate Structure
Bayer AG — The Deep-Pocket Parent
Bayer AG is a German pharmaceutical and life sciences conglomerate that acquired Monsanto in 2018 for $63 billion. By acquiring Monsanto, Bayer expressly inherited all of Monsanto’s Roundup product liability — a decision that has cost the company approximately $10 billion in settlements and verdicts so far, with the proposed $7.25 billion class settlement representing the next major tranche. Bayer is a deep-pocket defendant with global assets, and the Roundup liability has been a drag on its stock price and strategic direction for years. The Supreme Court ruling sent Bayer’s stock up seventeen to nineteen percent — its largest single-day percentage increase in more than two decades. The market is betting that the ruling substantially contains Bayer’s exposure. Whether that bet is correct depends on how aggressively plaintiffs pursue the surviving theories.
Monsanto Company — The Original Developer
Monsanto Company developed, manufactured, and marketed Roundup and its active ingredient, glyphosate, for decades. Monsanto designed the product formulation, conducted the safety research, and made the labeling decisions that are now at the center of the FIFRA preemption ruling. Monsanto is now a wholly-owned subsidiary of Bayer. The internal Monsanto documents — research on glyphosate’s carcinogenicity, alternative formulation studies, regulatory strategy files, and communications about the International Agency for Research on Cancer’s classification of glyphosate as “probably carcinogenic” — are the evidentiary backbone of surviving design defect and negligent design claims.
Bayer Crop Science Division — The St. Louis Connection
Bayer’s Crop Science Division is headquartered in Creve Coeur, Missouri, a St. Louis suburb that was Monsanto’s longtime home. This is why St. Louis is the epicenter of Roundup litigation. Monsanto’s decades-long presence in the St. Louis metro area means that corporate documents, former employees, and institutional knowledge are concentrated here. The St. Louis Circuit Court — the 22nd Judicial Circuit — has been a major venue for Roundup cases, and Missouri courts have historically been receptive venues for mass tort and product liability litigation. The proposed $7.25 billion class settlement is pending before Judge Timothy Boyer of the St. Louis Circuit Court, which means the approval process is happening right here in St. Louis, not in some distant federal courthouse.
For anyone who used Roundup in Missouri — whether as a gardener in St. Louis County, a farmer in the Bootheel, a landscaper in Jefferson City, or a groundskeeper at a school or park anywhere in the state — the fact that the litigation’s epicenter is your own backyard is strategically significant. The jury that decides what a case is worth, if you pursue individual litigation, is twelve people from your own community. The corporate documents are stored in your own metro area. The employees who made the decisions lived and worked here.
The Medicine: Non-Hodgkin’s Lymphoma and Glyphosate Exposure
What Non-Hodgkin’s Lymphoma Is
Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymphatic system — the body’s network of lymph nodes, spleen, thymus, and bone marrow that is part of the immune system. It begins in white blood cells called lymphocytes, which mutate and grow uncontrollably. There are more than seventy subtypes of NHL, ranging from indolent (slow-growing) to aggressive (fast-growing). Treatment depends on the subtype, the stage at diagnosis, and the patient’s overall health.
Treatment and Its Costs
Treatment regimens for NHL can include chemotherapy, immunotherapy (such as monoclonal antibody drugs like rituximab), radiation therapy, and in some cases stem cell transplants. For aggressive subtypes, treatment may begin immediately upon diagnosis and involve months of intensive therapy. For indolent subtypes, treatment may be deferred until symptoms progress — but the cancer is typically not curable, requiring ongoing surveillance and repeated treatment over years or decades.
The costs are enormous. Chemotherapy regimens, biologic drugs, imaging studies, bone marrow biopsies, hospital stays, and ongoing surveillance add up to hundreds of thousands of dollars for many patients. A stem cell transplant — used for relapsed or refractory disease — can cost well into six figures for a single treatment episode. And these costs do not end. NHL patients require years of follow-up scans, blood work, and specialist visits. Recurrence is common, and each recurrence brings a new treatment cycle and a new round of costs.
The Scientific Fault Line: IARC vs. EPA
The central scientific dispute in Roundup litigation is the conflict between two authoritative bodies:
The International Agency for Research on Cancer (IARC), which is part of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” (Group 2A) in 2015. IARC’s assessment was based on limited evidence of cancer in humans and sufficient evidence of cancer in experimental animals, plus strong mechanistic evidence.
The U.S. Environmental Protection Agency (EPA) has maintained that glyphosate is “not likely to be carcinogenic to humans.” This position has been the basis for EPA’s approval of Roundup’s label without a cancer warning — and it is the regulatory position that the Supreme Court’s FIFRA preemption ruling relied upon.
This conflict is not academic. It is the evidentiary fault line in every surviving Roundup claim. Under a design defect theory, the IARC classification and the underlying epidemiology support the argument that the product was unreasonably dangerous. Under the defense’s counter, the EPA’s position means the product was safe enough for market. Your case — if you pursue individual litigation — will be fought on this terrain. The expert witnesses we work with address both general causation (does glyphosate cause NHL?) and specific causation (did this plaintiff’s glyphosate exposure cause their NHL?). The post-ruling shift from failure-to-warn to design defect changes the expert landscape: design defect claims require proof of a safer alternative, not just proof of causation.
What the Family Sees
If you are reading this because someone you love has NHL, you already know what the disease looks like from the outside. The fatigue that does not go away. The swollen lymph nodes that appeared where there used to be nothing. The waiting room where you sit while someone you love gets infusion after infusion. The scan results that come back clean, then come back not clean, then come back clean again — a cycle that can last years. The fear that lives in the silence between doctor’s appointments. The financial pressure of medical bills that arrive faster than you can open them.
NHL is a serious cancer. It is treatable but often not curable. It changes the trajectory of a life. And if that change was caused by a product someone used for years without knowing the risk, the fact that the Supreme Court narrowed one legal theory does not mean the company that made the product is off the hook for every theory.
What Your Case Is Worth: Honest Numbers
We are not going to tell you your case is worth millions without knowing your facts. We are also not going to tell you it is worth nothing just because the Supreme Court ruled against one theory. Here is the honest framework.
Settlement-Track Cases: $25,000 to $500,000
If you participate in the proposed $7.25 billion class settlement, your individual allocation will depend on injury severity, exposure duration, treatment history, and age at diagnosis. The average across 67,000 claims is approximately $108,000, but individual amounts will range widely. Cases with shorter exposure, less severe disease, or weaker causation evidence will fall toward the lower end. Cases with long-term documented exposure, severe disease requiring extensive treatment, and strong medical records will fall toward the higher end.
Individual Design Defect Litigation: Higher Ceiling, Higher Risk
If you opt out of the settlement and pursue an individual design defect claim, the potential verdict value is substantially higher — comparable to pre-ruling Roundup verdicts, which reached multi-million-dollar ranges. But the risk is also higher. Design defect claims face aggressive Daubert challenges to general causation experts, protracted discovery, and the possibility of a defense verdict. Cases with the strongest design defect potential are those with:
- Documented long-term, frequent Roundup use (years of regular application)
- Confirmed NHL diagnosis with clear staging and treatment history
- Strong specific causation evidence (dose reconstruction, exposure duration, absence of competing risk factors)
- Severe disease presentation (Stage III/IV, extensive treatment, recurrence)
For these cases, seven-figure settlements or verdicts remain possible under design defect theories. But they require a willingness to litigate, patience for a multi-year process, and a legal team that understands the difference between a failure-to-warn claim and a design defect claim — and knows how to build the latter from the ground up.
Wrongful Death Cases
If your loved one died from NHL, wrongful death claims carry their own damages framework — the financial support the deceased would have provided, the loss of companionship, the conscious pain and suffering before death, and funeral and medical expenses. Missouri’s three-year wrongful death statute of limitations is a harder deadline than the five-year personal injury SOL, and it runs from the date of death, not the date of discovery. If you are approaching that window, waiting to see how the settlement process unfolds is a luxury you may not have.
Past results depend on the facts of each case and do not guarantee future outcomes. The figures above are framework ranges, not promises. Your individual case value depends on your specific facts, and the only way to know what your case is worth is to have it evaluated individually — not as a number in a class settlement grid, but as a human being with a specific exposure history and a specific cancer diagnosis.
Evidence Preservation: What Exists and How Fast It Disappears
Every Roundup case — whether settlement-track or individual litigation — depends on evidence. And evidence in toxic exposure cases has a shelf life. Here is what exists, who holds it, and how fast it can legally die.
Medical Records: Your NHL Diagnosis and Treatment History
Your complete medical records — including the pathology report confirming your NHL diagnosis, your staging workup, chemotherapy or immunotherapy records, hospital admission and discharge summaries, imaging studies, bone marrow biopsy results, and all follow-up surveillance records — are the foundation of your damages case and your specific causation proof.
Hospital and oncology records typically have retention windows of seven to ten years. For deceased plaintiffs, records may be archived or purged more quickly. Secure complete treatment records immediately, especially if the patient has died. Once a records retention window closes, the hospital may legally destroy the file, and the single best proof of your injury timeline is gone.
Purchase Receipts, Product Containers, and Usage Records
Evidence of your Roundup use — when you bought it, how often you used it, how long you used it, and in what quantities — is essential for specific causation. Many exposure events occurred ten to thirty years ago. Physical evidence may already be lost. But you can reconstruct exposure history through retailer purchase records (if you used a store loyalty card or credit card), employment records (if you used Roundup as part of your job), agricultural subsidy and pesticide application records, and witness affidavits from family members, coworkers, or employers who can attest to your usage patterns.
Memory fades. Records get destroyed. Witnesses pass away or move. The longer you wait to document your exposure history, the harder it becomes. This is not a theoretical concern — it is the single most common reason that otherwise valid toxic exposure cases weaken over time.
Internal Monsanto and Bayer Corporate Documents
The internal corporate documents — Monsanto’s own research on glyphosate’s carcinogenicity, alternative formulation studies, internal debates about the IARC classification, regulatory strategy communications, and marketing decisions — are the evidentiary backbone of design defect and negligent design claims. Many of these documents were produced in prior Roundup litigation and are available through discovery. But additional targeted discovery is needed for design defect theories, and corporate document retention policies and personnel turnover risk the loss of unproduced materials.
Monsanto’s decades-long St. Louis presence means that corporate documents, former employees, and institutional knowledge are concentrated in the metro area. This is a strategic advantage for cases filed in Missouri venues — the discovery targets are local, not scattered across the country.
EPA FIFRA Registration Files
EPA registration files, label approval correspondence, and scientific advisory committee records establish the regulatory framework and the scope of EPA’s safety review. These government records are relatively stable but should be formally requested through FOIA and regulatory channels. EPA administrative records may be scattered across multiple program offices, and pulling a complete file requires knowing what to ask for and where to ask.
Expert Causation Opinions
Expert opinions addressing both general causation (does glyphosate cause NHL?) and specific causation (did this individual’s exposure cause their disease?) are essential for surviving Daubert challenges and proving causation under any remaining theory. The IARC/EPA scientific conflict creates a contested causation landscape. Expert opinions need immediate development and must account for the post-ruling legal theory shift from failure-to-warn to design defect. This is not the kind of expert work that can be done in a few weeks. It requires months of record review, literature analysis, and report preparation.
The Bayer Playbook: How the Defense Will Use This Ruling
Bayer has a strategy, and you need to know what it is. Here are the plays we expect, and how each one is countered.
Play 1: “The Supreme Court Said You Can’t Sue Us”
Bayer will cite the Supreme Court ruling as broadly as possible, arguing that it precludes all Roundup litigation. They will send letters to plaintiffs’ counsel saying the case should be dismissed. They will file motions to dismiss citing the ruling. They will hope that you — and your lawyer — hear “Supreme Court ruled against Roundup plaintiffs” and conclude the case is over.
The counter: The ruling is limited to failure-to-warn. Design defect, negligent design, and fraudulent marketing claims are not preempted. A properly pleaded complaint that centers on design defect — not on what the label should have said — survives the ruling. The lawyer who reads the opinion and understands where the preemption line is drawn can replead around it. The lawyer who does not will dismiss your case unnecessarily.
Play 2: “The EPA Said It’s Safe”
Bayer will lean heavily on the EPA’s position that glyphosate is “not likely to be carcinogenic.” They will argue that if the federal regulator said the product is safe, no jury should be allowed to second-guess that determination.
The counter: The EPA’s regulatory position is not a scientific finding that glyphosate is safe. It is a regulatory classification made through a process that has itself been criticized. IARC — the world’s leading cancer research authority — classified glyphosate as “probably carcinogenic.” The conflict between these two bodies is itself evidence that the science is not settled. A design defect claim does not require the jury to find that the EPA was wrong. It requires the jury to find that the product was unreasonably dangerous — a standard that can coexist with regulatory approval. Products are recalled and found defective all the time after receiving regulatory clearance. Regulatory approval is a floor, not a ceiling.
Play 3: “Your Cancer Came From Something Else”
Bayer will argue that non-Hodgkin’s lymphoma has many causes — genetic factors, viral infections, other chemical exposures, age — and that you cannot prove your specific cancer came from Roundup rather than from something else.
The counter: This is the standard defense playbook in every toxic tort case, and it is answerable. Specific causation is proven through dose reconstruction (how much glyphosate you were exposed to and for how long), the absence of competing risk factors, the temporal relationship between exposure and diagnosis, and the epidemiological evidence showing elevated NHL risk in glyphosate-exposed populations. An expert toxicologist and oncologist can build a specific causation opinion that ties your disease to your exposure. The defense’s “it could have been anything” argument is weaker when the plaintiff has documented, long-term, high-frequency exposure and no significant competing risk factors.
Play 4: “Take the Settlement or Get Nothing”
Bayer will use the Supreme Court ruling to depress settlement values, arguing that the ruling reduces the value of every case and that the class settlement is the best you will get. They will create urgency around the settlement approval process to push claimants into participating before they have fully evaluated their individual case strength.
The counter: The ruling does reduce the value of failure-to-warn claims. It does not reduce the value of design defect claims to zero. A claimant with strong long-term exposure and severe NHL may have a case worth substantially more than the settlement allocation. But the decision to opt out must be made with full information — not under artificial pressure from a settlement administrator. The settlement approval process has a timeline, and the opt-out deadline will be published. You have time to get your case evaluated. Use it.
Play 5: “We Already Paid $10 Billion — We’re Done”
Bayer will frame the $10 billion already paid and the $7.25 billion class settlement as the end of its Roundup liability, arguing that the company has made things right and further litigation is unnecessary and unfair.
The counter: $10 billion across tens of thousands of claims, plus $7.25 billion across 67,000 more, is not “making things right” for an individual who used Roundup for twenty years, developed a cancer that may kill them, and was never warned. The aggregate numbers sound large. The individual allocations are modest. And Bayer’s decision to settle does not extinguish the legal rights of claimants who choose not to participate in the class. Containment is not closure.
The Proof Story: How a Surviving Roundup Case Is Built
Here is how a Roundup case that survives the Supreme Court ruling is actually built, step by step.
Week one: The preservation demand goes out. Letters are sent to Bayer, Monsanto, and any relevant third parties ordering them to preserve all documents related to glyphosate formulation, safety research, alternative designs, internal communications about cancer risk, and marketing materials. This freezes the evidence before routine retention policies can destroy it.
Weeks two through four: Medical records are pulled — the complete NHL file, from pathology to treatment to surveillance. Exposure history is documented through purchase records, employment records, witness affidavits, and any available product containers or receipts. The client’s specific exposure timeline is reconstructed in detail: when they started using Roundup, how often, how much, for how many years, and under what conditions.
Months one through three: Expert witnesses are retained. A toxicologist addresses general causation — the link between glyphosate and NHL. An oncologist addresses specific causation — whether this plaintiff’s NHL is consistent with glyphosate exposure. A product design expert addresses the design defect element — whether a safer alternative formulation was feasible and whether the product was unreasonably dangerous. A forensic economist calculates the lifetime cost of the disease — medical expenses, lost wages, lost earning capacity, and the full economic impact of the cancer.
Months three through twelve: Discovery begins. Written interrogatories go to Bayer. Document demands target internal Monsanto research files, alternative formulation studies, IARC response strategy documents, marketing materials, and regulatory communications. Depositions of corporate witnesses — the scientists who studied glyphosate, the executives who decided whether to warn, the marketing professionals who promoted the product as safe — are scheduled and taken under oath.
Year one and beyond: The case moves toward trial or settlement. Daubert motions are filed — Bayer will try to exclude your causation experts; you will try to exclude theirs. Summary judgment motions are filed — Bayer will argue the Supreme Court ruling bars your claims; you will argue your design defect theory is not preempted. If the case survives these motions, it proceeds to trial or to a settlement conference where the threat of a trial drives the number.
This is not a fast process. A well-built design defect case takes twelve to twenty-four months from filing to trial, sometimes longer. But the number at the end is built from all of it — the frozen evidence, the expert opinions, the deposition testimony, and the corporate documents that show what the company knew and when it knew it.
The First 72 Hours: What to Do Now
If you or a loved one used Roundup and has been diagnosed with non-Hodgkin’s lymphoma, here is what to do in the next three days.
Day one: Gather your medical records. If you have been diagnosed with NHL, contact your oncologist’s office and request your complete file — pathology reports, staging workup, treatment records, imaging reports, and all follow-up notes. If your loved one has died from NHL, request their records immediately. Hospital retention windows are finite, and once they close, the records may be legally destroyed.
Day two: Document your Roundup use history. Write down everything you can remember: when you started using Roundup, how often you used it, how much you used each time, where you bought it, what size containers you purchased, whether you used it for personal gardening, professional landscaping, agriculture, or groundskeeping, and when you stopped using it. If you have old purchase receipts, product containers, or photographs showing Roundup in your garage or shed, preserve them. If family members or coworkers can attest to your usage, ask them to write down what they remember while their memory is fresh.
Day three: Get your case evaluated. Not by a settlement administrator. Not by a call center. By a lawyer who understands the difference between failure-to-warn and design defect, who knows the Supreme Court ruling’s actual scope, and who can tell you whether your case is better suited to the class settlement or to individual litigation. This evaluation should be free, confidential, and specific to your facts — not a blanket recommendation based on a news headline.
Do not sign anything from a settlement administrator or class notice until you have had your case individually evaluated. The opt-out decision is, in most class structures, irreversible. Once you are locked into the settlement grid, you generally cannot pursue an individual claim. The time to get advice is before you sign, not after.
Do not post about your case on social media. Do not give recorded statements to insurance adjusters, claims administrators, or anyone representing Bayer or Monsanto. Do not discuss your Roundup use or your cancer diagnosis in any forum where it can be quoted back to you later.
Do not wait to see how the settlement process unfolds before talking to a lawyer. The settlement approval process has a timeline, and the opt-out deadline — the date by which you must decide whether to participate in the class or pursue your own case — will be published in the class notice. If you miss that deadline, your choice is made for you. You are in the class, and your individual design defect claim is gone.
The Science Behind Surviving Claims: What the Generalist Misses
Here is what a lawyer who does not live in this litigation misses — and what costs you real money.
The Supreme Court ruled on FIFRA preemption of failure-to-warn claims. That is one theory. The generalist reads the headline, hears “Bayer won,” and tells the client the case is over. The lawyer who has actually read the opinion sees the narrow holding — failure-to-warn only — and starts thinking about how to replead the same facts as a design defect claim.
But design defect is not just failure-to-warn with a different label. It requires a different proof architecture. You need a safer alternative design — a formulation or delivery system that would have reduced the cancer risk without destroying the product’s commercial viability. That requires a product design expert, not just a toxicologist. You need to show that the defendant knew about the danger at the time of manufacture — which means internal corporate documents, not just the IARC classification. You need to prove that the product was unreasonably dangerous — a risk-utility analysis that weighs the product’s benefits against its risks and asks whether a reasonable manufacturer would have put it on the market in this form.
The generalist files the complaint that gets dismissed because it still reads like a failure-to-warn claim with the words “design defect” pasted on top. The lawyer who understands the ruling pleads a genuine design defect claim that does not depend on the label at all — and survives the motion to dismiss that Bayer will file against every surviving complaint.
This is the difference that ends cases before they start, or keeps them alive. It is the difference between walking away with a $25,000 settlement allocation and pursuing a case that may be worth ten or twenty times that.
Frequently Asked Questions
Is my Roundup case over because of the Supreme Court ruling?
No, not necessarily. The Supreme Court’s ruling is specifically limited to failure-to-warn claims — the theory that Monsanto and Bayer should have put a cancer warning on the product label. Design defect claims, negligent design claims, fraudulent marketing claims, and breach of express warranty claims appear to survive the ruling because they do not depend on label content or require label changes beyond what the EPA approved. If your case was built entirely on failure-to-warn, it faces serious challenges. If your case can be built on design defect — that the product’s formulation itself was unreasonably dangerous — it may survive.
Should I participate in the $7.25 billion class settlement or opt out?
This depends entirely on your individual facts. If you have documented long-term Roundup exposure and a confirmed NHL diagnosis with significant treatment, your case may be worth more than the settlement allocation, and opting out to pursue an individual design defect claim may be the right choice. If your exposure was shorter or your causation evidence is weaker, the settlement may provide meaningful compensation with less risk. This decision must be made with full information about your individual case strength, not based on a news headline. The opt-out deadline in the class settlement will be published in the class notice, and it is irreversible in most class structures.
How long do I have to file a Roundup lawsuit in Missouri?
Missouri’s personal injury statute of limitations gives you five years from the date the cause of action accrues. For toxic exposure cases involving latent diseases like cancer, the clock typically starts when you discovered, or reasonably should have discovered, that your injury was connected to the product — not the date you were exposed. For wrongful death claims, Missouri’s statute of limitations is three years from the date of death, which is a harder deadline. These deadlines are state-specific and the discovery rule’s application depends on your individual facts. Do not assume you have plenty of time — confirm the deadline with a lawyer who can evaluate your specific situation.
What if I already have a lawyer and they say my case is over?
Get a second opinion. The Supreme Court ruling is new, and its application to specific cases is still being sorted out by courts across the country. A lawyer who tells you your case is over without distinguishing between failure-to-warn and design defect may not have fully analyzed the ruling’s scope. The ruling is narrow. The surviving theories are real. And the decision to dismiss your case should be based on a specific analysis of your facts under the surviving legal theories, not a blanket conclusion drawn from a headline.
What evidence do I need for a Roundup lawsuit?
You need three categories of evidence. First, medical evidence: your NHL diagnosis, pathology reports, staging, treatment records, and ongoing surveillance — proving the injury and its severity. Second, exposure evidence: documentation of your Roundup use — when, how often, how long, in what quantities — through purchase records, employment records, product containers, and witness testimony. Third, corporate evidence: internal Monsanto and Bayer documents showing what the company knew about glyphosate’s cancer risks, whether safer alternatives were studied, and how the product was marketed. The first two categories are in your control — gather them now. The third is obtained through discovery once a lawsuit is filed.
Can I still sue if I used Roundup years ago?
Yes, potentially. The latency between glyphosate exposure and an NHL diagnosis can span years or decades. Missouri’s discovery rule means the statute of limitations typically starts when you discovered, or should have discovered, the connection between your exposure and your disease — not when you were exposed. If you were diagnosed with NHL recently and only recently learned that Roundup may have contributed, your clock may have started recently. But this is a fact-specific determination, and some states have statutes of repose that impose outer deadlines regardless of discovery. Do not assume you are too late — and do not assume you have plenty of time. Get it checked.
What if my loved one died from non-Hodgkin’s lymphoma?
If your loved one died from NHL and you believe Roundup exposure contributed, you may have a wrongful death claim. Missouri’s wrongful death statute of limitations is three years from the date of death — shorter than the five-year personal injury SOL, and running from a harder date. If the three-year window is approaching or has passed, you need to talk to a lawyer immediately. Wrongful death damages include the financial support the deceased would have provided, the loss of companionship and guidance, conscious pain and suffering before death, and medical and funeral expenses. If your loved one’s case was strong on design defect theory — long-term documented exposure, severe disease, minimal competing risk factors — the estate’s claim may carry significant value even after the Supreme Court ruling.
How much does it cost to hire a lawyer for a Roundup case?
With us, it costs nothing upfront. We work on contingency — we do not get paid unless we win your case. The fee is 33.33% of the recovery before trial and 40% if the case goes to trial. The consultation is free. We advance the costs of litigation — filing fees, expert witness fees, record retrieval costs — and those costs are repaid from the recovery if we win. If we do not win, you owe us nothing for our time. This is not generosity. It is how product liability and toxic tort cases work — the contingency fee gives people access to the courthouse against billion-dollar defendants without having to pay hourly rates they could never afford.
What is FIFRA and why does it matter to my case?
FIFRA is the Federal Insecticide, Fungicide, and Rodenticide Act — the federal law that governs pesticide registration, labeling, and sale in the United States. Under FIFRA, the EPA must approve all pesticide labels before the products can be distributed. The Supreme Court’s ruling holds that FIFRA’s federal labeling scheme preempts state-law failure-to-warn claims — meaning a state tort lawsuit cannot require a cancer warning on a pesticide label beyond what the EPA approved. This is why failure-to-warn claims are now largely foreclosed. But FIFRA governs labels. It does not govern product design. A claim that the product’s formulation is unreasonably dangerous — a design defect claim — does not require a label change and does not collide with FIFRA’s labeling authority. That is the legal seam the surviving claims pass through.
Should I sign the class settlement notice I received?
Not until you have had your case individually evaluated by a lawyer who understands the surviving legal theories. The class settlement may be the right path for you. But the decision to participate is, in most class structures, irreversible — once you are in, you cannot opt out later to pursue an individual claim. And the opt-out deadline will be published in the class notice, which means you have a finite window to make this decision. Signing the notice without understanding whether your case is worth more as an individual design defect claim is a decision made in the dark. Get a light turned on first.
Does the Supreme Court ruling affect cases outside Missouri?
Yes. The Supreme Court’s ruling is a federal preemption decision, which means it applies nationwide. State courts in every state must follow it on the failure-to-warn question. However, the surviving theories — design defect, negligent design, fraudulent marketing — are governed by state product liability law, which varies by state. Missouri’s pure comparative fault rule, its lack of damage caps in product liability cases, and its history as a receptive venue for mass tort litigation make it a strategically significant jurisdiction. But the ruling’s effect on failure-to-warn claims is the same everywhere: those claims are largely preempted.
Who We Are and How We Work
We are Attorney911 — The Manginello Law Firm, PLLC. We have been in practice since July 18, 2001 — more than twenty-four years. Our managing partner is Ralph P. Manginello, a Texas-licensed trial attorney with 27+ years of courtroom experience, including federal court admission. Ralph was a journalist before he was a lawyer, which means he reads decisions like the Supreme Court’s FIFRA preemption ruling the way a reporter reads a story — for what it actually says, not for what someone wants you to think it says. He is a member of the Texas Trial Lawyers Association, the Houston Bar Association, and the National Association of Criminal Defense Lawyers, and he has led cases ranging from catastrophic injury to commercial litigation to the active $10 million hazing lawsuit against the University of Houston and Pi Kappa Phi.
Our associate attorney is Lupe Peña, a Texas-licensed trial attorney with 13+ years of experience. Before joining this firm, Lupe spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue claims exactly like yours. He sat across the table from the people who are now sitting across from you. He knows how claim valuation software works, how IME doctors are selected, how surveillance is deployed, and how delay tactics are engineered. He now uses that knowledge for injured clients. Lupe is fluent in Spanish and conducts full consultations in Spanish without an interpreter — and we say that with pride, because it means we serve families in the language they actually speak.
We handle toxic tort and product liability cases in Missouri, working with local counsel and appearing pro hac vice where required. We do not claim an office in Missouri. We do not claim a Missouri bar admission. What we claim is the experience, the resources, and the trial instinct to handle complex product liability litigation — and the honesty to tell you when the settlement is the right path and when individual litigation is.
We offer a free consultation, twenty-four hours a day, seven days a week, with live staff — not an answering service. There is no fee unless we win your case. The fee is 33.33% before trial, 40% if the case goes to trial. We advance the costs of litigation. If we do not win, you owe us nothing for our time.
Past results depend on the facts of each case and do not guarantee future outcomes. Our aggregate recoveries exceed $50 million — a figure that includes cases across multiple practice areas and states. We tell you that not to impress you, but to tell you we have been in the arena. The Roundup litigation is a new chapter, and the Supreme Court’s ruling has changed the landscape. What has not changed is our approach: read the law carefully, build the proof methodically, and fight for the full value of the harm done.
What the First Call Feels Like
When you call 1-888-ATTY-911, you will talk to a real person. Not a chatbot. Not a voicemail. Not a call center that takes your number and promises someone will call you back. A live staff member, twenty-four hours a day, who will gather basic information and connect you with an attorney.
The consultation is free. It is confidential. It costs you nothing but the time it takes to tell your story. And the first thing we will do is listen — not talk, not sell, not promise. Listen to when you started using Roundup. How often. How long. When you were diagnosed. What your treatment has been. What your doctor has told you. What you have heard about the Supreme Court ruling. What you are afraid of.
Then we will tell you the truth. We will tell you whether your case is strong, weak, or somewhere in between. We will tell you whether the class settlement is the right path for your specific facts or whether you should consider opting out. We will tell you which legal theory — design defect, negligent design, marketing, warranty — fits your facts. We will tell you what evidence we need and how fast we need it. And if we are not the right fit for your case — if the settlement is clearly your best option and you do not need a trial lawyer — we will tell you that too, and point you toward the resources that serve you better.
That is what a free consultation should be. Not a sales pitch. An honest assessment from people who have been doing this for decades.
Why St. Louis Matters to Your Case
St. Louis is not just where this story is happening. It is where the evidence lives. Monsanto built its empire here. Bayer’s Crop Science Division still operates here, in Creve Coeur, in the buildings where Monsanto once decided what went on the Roundup label and what did not. The St. Louis Circuit Court — where the $7.25 billion class settlement is pending before Judge Boyer — is a court that has handled Roundup cases for years. The juries are drawn from a community where people know what Monsanto was, what Bayer is, and what Roundup does.
If your case proceeds as individual litigation rather than through the class settlement, the venue matters. Missouri’s pure comparative fault rule, its lack of damage caps in product liability cases, and its history of substantial plaintiff verdicts in mass tort cases make it a jurisdiction where a well-built design defect claim has a real chance of reaching a jury that will listen. Not every state is like that. Some states have caps that would limit your recovery. Some states have modified comparative fault rules that would bar your claim if you were partly at fault. Some states have courts that are less receptive to product liability claims.
Missouri is different. And if you live here, or if you were exposed to Roundup here, that difference is working in your favor — even after the Supreme Court ruling.
Hablamos Español. Lupe Peña conducts full consultations in Spanish without an interpreter, and our bilingual staff serves families in the language they actually speak.
The Bottom Line
The Supreme Court ruled against failure-to-warn claims in Roundup litigation. That is real. It is significant. It changes the landscape. But it is not the end of every case, and it is not the end of your case unless you let it be.
Design defect claims survive. Negligent design claims survive. Fraudulent marketing claims survive. The $7.25 billion class settlement is moving forward. And the decision of whether to participate in that settlement or pursue an individual claim under the surviving theories is the most important decision you will make in this litigation.
Make it with your eyes open. Make it with a lawyer who has read the ruling, understands the surviving theories, and can evaluate your specific facts against the legal landscape that exists today — not the one that existed before the ruling, and not the one Bayer’s press releases describe.
Call us at 1-888-ATTY-911. The consultation is free. The call is confidential. The staff is live, twenty-four hours a day. There is no fee unless we win your case.
You used a product you were told was safe. You got sick. The company that made the product just won a major legal battle — but it did not win the war. The question is whether you fight the battles that remain or walk away. That decision is yours. We are here to help you make it with the truth in front of you, not behind you.
Contact us. The conversation costs nothing. Not having it could cost everything.